AVEO Pharma

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AVEO is a late-stage biopharmaceutical company focused on the discovery and development of targeted cancer therapeutics. AVEO's proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets and therapies. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR, ErbB3 and NOTCH), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals, Schering-Plough, and Biogen Idec. The company was established in 2001 and is based in Cambridge, Massachusetts.

AstraZeneca

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced the presentation of results from the Phase 1b portion of the Phase 1b/2 DEDUCTIVE clinical trial of tivozanib (FOTIVDA®), AVEO's vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) drug candidate, in combination with IMFINZI® (durvalumab), AstraZeneca's (LSE/STO/Nasdaq: AZN) human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in patients with advanced or metastatic hep

AVEO Oncology Announces Results from Phase 1b Portion of DEDUCTIVE Study of Tivozanib (FOTIVDA®) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today highlighted its recent progress and outlined its 2021 outlook. “We remain keenly focused on building out our commercial team ahead of the potential U.S. launch of tivozanib as a treatment for relapsed or refractory renal cell carcinoma (RCC), including the addition of Dr. Corinne Epperly to our Board of Directors,” said Michael Bailey, president and chief executive officer of AVEO. “If approved, we believe tivozanib has the potential t

AVEO Oncology Highlights Recent Progress and 2021 Outlook

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will participate in two upcoming virtual investor conferences: H.C. Wainwright Virtual BioConnect Conference Date: Monday, January 11 – Thursday, January 14 B. Riley Virtual Oncology Investor Conference Date: Wednesday, January 20 Time: 1:30 PM Eastern Time A replay of the pre-recorded H.C. Wainwright presentation can be accessed on Monday, January 11, 2021 i

AVEO Oncology Announces Participation at Two Upcoming Investor Conferences

BOSTON, Mass.--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 5:20 p.m. Eastern Time. Following the presentation, Mr. Bailey will be joined by other members of AVEO's management team for a question-and-answer session. A live webcast of the presentation and question-and-answer session can be accessed by visiting the

AVEO Oncology Announces Webcast of Presentation at the 39th Annual J.P. Morgan Healthcare Conference

AVEO is preparing for the potential U.S. commercial launch for Tivozanib in R/R RCC. The FDA has set the PDUFA Date for March 31st, 2021.

AVEO Oncology: Managing A Position Ahead Of Tivozanib's PDUFA

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020 at 11:20 a.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company's website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentation date. About AVEO Pharmaceut

AVEO Oncology to Present at the Stifel 2020 Virtual Healthcare Conference

AVEO (AVEO) delivered earnings and revenue surprises of -37.50% and -5.39%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

AVEO Pharmaceuticals (AVEO) Reports Q3 Loss, Lags Revenue Estimates

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today reported financial results for the third quarter ended September 30, 2020 and provided a business update. “In advance of the Food and Drug Administration's (FDA) March 31, 2021 Prescription Drug User Fee Act (PDUFA) target action date for our tivozanib New Drug Application, we are actively building out AVEO's U.S. commercial infrastructure to support the FDA-pending U.S. launch of tivozanib in relapsed or refractory renal cell carcinom

AVEO Oncology Reports Third Quarter 2020 Financial Results and Provides Business Update

BOSTON & HEMEL HEMPSTEAD, England--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) and EUSA Pharma today announced that previously reported results from the Phase 1b/2 TiNivo study of oral (PO) tivozanib, AVEO's next-generation vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI) drug candidate, in combination with intravenous (IV) nivolumab (OPDIVO®, Bristol-Myers Squibb), an immune checkpoint, or PD-1, inhibitor, for the treatment of advanced or metastatic renal ce

AVEO Oncology and EUSA Pharma Announce Annals of Oncology Publication of Data from Phase 1b/2 TiNivo Study in Renal Cell Carcinoma

On AVEO Pharmaceuticals' (AVEO) third-quarter earnings call, investor focus will be on the updates related to its NDA that seeks an approval for tivozanib to treat RCC in the United States.

What Awaits AVEO Pharmaceuticals (AVEO) in Q3 Earnings?

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced the appointment of David Crist as Vice President of Sales. In this role, Mr. Crist will be responsible for building out AVEO's sales force in anticipation of the potential approval and launch of tivozanib, the Company's next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), as a treatment for relapsed or refractory renal cell carcinoma. “We are excited to welcome David to the AVEO t

AVEO Oncology Announces Appointment of David W. Crist as Vice President of Sales

AVEO Pharmaceuticals (AVEO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Increased Earnings Estimates Seen for AVEO Pharmaceuticals (AVEO): Can It Move Higher?

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that final overall survival (OS) results from its Phase 3 TIVO-3 study were published in the journal European Urology. TIVO-3 is the Company’s pivotal Phase 3 trial comparing tivozanib, AVEO’s next-generation vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI) drug candidate, to sorafenib in third and fourth line renal cell carcinoma (RCC).

AVEO Oncology Announces European Urology Publication of Final Overall Survival Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma

As of late, it has definitely been a great time to be an investor AVEO Pharmaceuticals.

AVEO's Shares March Higher, Can It Continue?

AVEO reclaims complete rights to ficlatuzumab from Biodesix for an undisclosed sum. The candidate is being developed for several cancer indications.

AVEO Acquires Full Global Rights to Ficlatuzumab From Biodesix

AVEO (AVEO) reported earnings 30 days ago. What's next for the stock?

AVEO (AVEO) Up 20.7% Since Last Earnings Report: Can It Continue?

AVEO Pharmaceuticals (AVEO) seeks an FDA nod for Fotivda in the United States to treat relapsed or refractory RCC. A decision from the regulatory agency is expected on Mar 31, 2021.

AVEO's NDA for Fotivda on Track, FDA Verdict Due Next Year

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has regained full global rights to ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody which binds to the HGF ligand with high affinity and specificity to inhibit HGF/c-Met biological activities. AVEO also announced today that it plans to fund the clinical manufacture of ficlatuzumab to enable a potential registrational Phase 3 clinical trial in head and neck squamous cell cancer (HNSCC), as

AVEO Oncology Regains Full Global Rights to Ficlatuzumab

AVEO (AVEO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AVEO (AVEO) Upgraded to Buy: What Does It Mean for the Stock?

AVEO (AVEO) reports a narrower-than-expected loss but misses sales estimates in the second quarter of 2020.

AVEO Pharmaceuticals' (AVEO) Q2 Earnings Surpass Estimates

AVEO (AVEO) delivered earnings and revenue surprises of 17.65% and -49.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Lags Revenue Estimates

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today reported financial results for the second quarter ended June 30, 2020 and provided a business update. “The first half of 2020 was one of the most important periods in AVEO’s history to date, with the successful completion of the TIVO-3 study and the acceptance for filing and substantive review of a New Drug Application (NDA) for tivozanib as a treatment for relapsed or refractory renal cell carcinoma (RCC),” said Michael Bailey, presid

AVEO Oncology Reports Second Quarter 2020 Financial Results and Provides Business Update

AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: AVEO Pharmaceuticals (AVEO) Q2 Earnings Expected to Decline

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has earned a $2.8 million development milestone payment from partner Kyowa Kirin Co., Ltd. (Kyowa Kirin).

AVEO Oncology Announces $2.8M Development Milestone Earned from Kyowa Kirin

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced the closing of its previously announced underwritten public offering of 9,725,000 shares of its common stock, which includes the partial exercise by the underwriters of their option to purchase an additional 1,225,000 shares, at a price to the public of $5.25 per share. The aggregate gross proceeds to AVEO from the offering were approximately $51.1 million, before deducting underwriting discounts and commissions and offering

News for AVEO Pharma Stock (AVEO)